MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Traws Pharma has completed the Phase I clinical trials of tivoxavir marboxil, a single-dose drug for treating or preventing ...

The trial builds off the previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in patients ...

Medidata has announced the extension of its partnership of 13 years with Tigermed to enhance clinical trial processes.

GlobalData epidemiologists forecast a rise in dementia cases in the US from 2.97 million in 2024 to 4.06 million by 2033.

Tris Pharma has reported positive outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol to treat moderate-to-severe ...

Rigel has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, to ...

Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

The Clinical Trials Arena spoke to industry experts about what challenges the sector can expect to face in 2025.

The US FDA has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer healthcare business, Opella.

Synthetic chemicals called per- and polyfluoroalkyl substances (PFAS) have been accumulating in the environment since their ...

YolTech Therapeutics is set to commence a trial of its in vivo gene editing therapy, YOLT-204, aimed at treating TDT.